iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

Inclusion Criteria: * Patients with histologically confirmed metastatic pancreatic ductal adenocarcinoma harboring KrasG12D mutation * Patients must have documented progression or stable disease on one or more lines of systemic therapy. If stable disease, patient must have completed at least 4 months of chemotherapy with cytotoxic therapy * KrasG12D mutation status will be informed from any previous routine molecular profiling (using commercial assays such as Foundation One, Caris, Oncomine or other) of tissue or blood. Additional KrasG12D mutation status may be confirmed using tissue biopsy or blood prior to enrolling into the trial * ECOG (Eastern Cooperative Oncology Group) performance status of 0-1 * Absolute neutrophil count (ANC) more or equal to 1,500 cells/mm3 * Platelets more or equal to 100,000/ul * Hemoglobin more than 9.0 g/dL * Total bilirubin between 1 and 1.5 mg/dL * AST (aspartate aminotransferase) and ALT (alanine transaminase) less than 2.5 x ULN (upper limit of normal) * Alkaline phosphatase less than 2.5 x ULN * Creatinine less than 1.5 gm/dL * In patients with known Gilbert's syndrome, direct bilirubin less or equal to 1.5 x ULN will be used as organ function criteria, instead of total bilirubin * Negative serum pregnancy test in women with childbearing potential (WOCBP) defined as not post-menopausal for 12 months or no previous surgical sterilization, within one week prior to initiation of treatment. WOCBP must be using an adequate method of contracept…